LEP and diabetes mellitus: Our findings show that fenofibrate (1) reduced circulating levels IL-8 and TNF-α, which may alleviate insult to the intestinal barrier, and (2) increased circulating levels of IL-6, which may be advantageous in DM through stimulation of lipolysis, beta-oxidation, and leptin secretion56.